Abstract
Despite being long lived, anthracyclines remain the “evergreen” drugs in clinical practice of oncology, showing a potent effect in inhibiting cell growth in many types of tumors, including brain neoplasms. Unfortunately, they suffer from a poor penetration into the brain when intravenously administered due to multidrug resistance mechanism, which hampers their delivery across the blood brain barrier.
In this paper, we summarize the current literature on the role of anthracyclines in cancer therapy and highlight recent efforts on 1) development of tumor cell resistance to anthracyclines and 2) the new approaches to brain drug delivery across the blood brain barrier.
Keywords: Anthracyclines, blood brain barrier, brain diseases, drug delivery systems, drug efflux proteins, multidrug resistance.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:The Use of Anthracyclines for Therapy of CNS Tumors
Volume: 15 Issue: 6
Author(s): Martina da Ros, Anna Lisa Iorio, Maurizio Lucchesi, Alessia Stival, Maurizio de Martino and Iacopo Sardi
Affiliation:
Keywords: Anthracyclines, blood brain barrier, brain diseases, drug delivery systems, drug efflux proteins, multidrug resistance.
Abstract: Despite being long lived, anthracyclines remain the “evergreen” drugs in clinical practice of oncology, showing a potent effect in inhibiting cell growth in many types of tumors, including brain neoplasms. Unfortunately, they suffer from a poor penetration into the brain when intravenously administered due to multidrug resistance mechanism, which hampers their delivery across the blood brain barrier.
In this paper, we summarize the current literature on the role of anthracyclines in cancer therapy and highlight recent efforts on 1) development of tumor cell resistance to anthracyclines and 2) the new approaches to brain drug delivery across the blood brain barrier.
Export Options
About this article
Cite this article as:
Ros da Martina, Iorio Lisa Anna, Lucchesi Maurizio, Stival Alessia, Martino de Maurizio and Sardi Iacopo, The Use of Anthracyclines for Therapy of CNS Tumors, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (6) . https://dx.doi.org/10.2174/1871520615666150407155319
DOI https://dx.doi.org/10.2174/1871520615666150407155319 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiovascular Risk Factors, Metabolic Complications, & the Natural Course of CKD in Children
Current Hypertension Reviews Application and Future Prospect of Extracellular Matrix Targeted Nanomaterials in Tumor Theranostics
Current Drug Targets Interest of Antioxidant Agents in Parasitic Diseases. The Case Study of Coumarins
Current Topics in Medicinal Chemistry Use of Medication in Coronary Imaging by CT
Current Medical Imaging Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry TakoTsubo Cardiomyopathy A Short Review
Current Cardiology Reviews The Role of the Chemokines in Myocardial Ischemia and Reperfusion
Current Vascular Pharmacology Relaxin, Insulin and Diabetes: An Intriguing Connection
Current Diabetes Reviews Neuro-Psychological Pattern in Patients Suffering from Primitive Dilated Cardiomyopathy with Impairment in Executive Function
Current Neurovascular Research Sympathetic Overactivity in Hypertension and Cardiovascular Disease
Current Vascular Pharmacology Signaling Epicenters: The Role of Caveolae and Caveolins in Volatile Anesthetic Induced Cardiac Protection
Current Pharmaceutical Design Potential of Resveratrol in Preventing the Development of Heart Failure
Current Chemical Biology Gene Clusters, Molecular Evolution and Disease: A Speculation
Current Genomics Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome?
Current Pharmaceutical Design Stem Cells: Clinical Trials Results The End of the Beginning or the Beginning of the End?
Cardiovascular & Hematological Disorders-Drug Targets Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?
Current Vascular Pharmacology Modulation of Fatty Acids Oxidation in Heart Failure by Selective Pharmacological Inhibition of 3-Ketoacyl Coenzyme-A Thiolase
Current Clinical Pharmacology Emerging Role for RBM20 and its Splicing Substrates in Cardiac Function and Heart Failure
Current Pharmaceutical Design Molecular Modeling Investigation of Some New 2-mercaptoimidazoles
Current Computer-Aided Drug Design Safety Analysis and Improved Cardiac Function Following Local Autologous Transplantation of CD133+ Enriched Bone Marrow Cells After Myocardial Infarction
Current Neurovascular Research